[BREAKING] Hemerion obtains the FDA clearance for its next US clinical trial

Therapeutic solutions

Video Header - Therapeutic solutions

Hemerion addresses upfront management of newly diagnosed glioblastoma, during surgery, before any adjuvant treatment or drug can be delivered, making Hemerion technology a breakthrough innovation that significantly improves both survival and quality of life in patients.

Hemerion solutions complement and enhance glioblastoma current treatment

Glioblastoma is the most common and most devastating malignant brain tumor. There is no known cure for this disease: the tumor progression is only slowed and reduced through surgery, radiotherapy and chemotherapy.
Hemerion technology dramatically improves the existing treatment outcomes, patients’ survival and quality of life.

More about glioblastoma and treatment options available

Medical imaging

Hemerion solutions bring together novel pharmaceutical and photonic therapies

Hemerion technology associates a drug (Pentalafen®) with innovative photonic treatments (Heliance Solution). Molecule used for our treatment selectively bond to cancer cells and destroy them when activated by specific laser light. Brain tumor cells are killed wherever light penetrates.

More about our technology

Hemerion solutions are already clinically tested

Hemerion technology was first clinically evaluated in 2018 among 10 patients newly diagnosed with GBM and before any adjuvant treatment was delivered.

Complimentary clinical trials are still under way.

More about our clinical results

Brain medical image
Doctor analyzing x-rays

Solutions to tackle other types of cancers

Hemerion further develops its technology to tackle other types of cancers.

More about our R&D programs

Demos and training

Hemerion team can demonstrate its technology on premises. Do not hesitate to contact us!

Contact Hemerion